CG vs RVTY Comparison

The Carlyle Group is one of the world's largest alternative-asset managers, with $434.6 billion in total AUM, including $307.3 billion in fee-earning AUM, at the end of June 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 34% of fee-earning AUM and 58% of base management fees during 2023), global credit (51% and 27%) and investment solutions (15% and 15%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.